CriticalAntigout agents×Antiviral for systemic use, HIV-1 protease inhibitor; used only with a pharmacokinetic booster (ritonavir or cobicistat)
Updated · Methodology
Mechanism
CYP3A4 is the main enzyme that metabolises colchicine, and the efflux transporter P-glycoprotein carries it out of cells (colchicine label, US Food and Drug Administration, FDA). Colchicine has a narrow therapeutic margin and is extremely toxic in overdose. Its clearance falls in renal impairment and may drop markedly in hepatic impairment (colchicine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Darunavir is taken only with a booster (ritonavir or cobicistat), and in this regimen it inhibits CYP3A and P-glycoprotein (darunavir SmPC, European Medicines Agency, EMA). The combination has not been studied, but the darunavir SmPC expects colchicine levels to rise (darunavir SmPC, AEMPS). The US colchicine label lists darunavir/ritonavir among the strong CYP3A4 inhibitors that markedly raise colchicine plasma levels (colchicine FDA label).
Symptoms
The first signs of colchicine toxicity are nausea, vomiting, abdominal pain and diarrhoea. High doses cause profuse diarrhoea and gastrointestinal bleeding (colchicine summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). In severe poisoning, symptoms may appear after a delay of about 3 hours on average. They begin with fluid loss, electrolyte disturbances and low blood pressure. After 24–72 hours, the patient may develop multi-organ failure, acute kidney failure, confusion and coma, neuropathy, myocardial depression and arrhythmias, a fall in all blood cell lines (pancytopenia), respiratory failure and a clotting disorder (colchicine SmPC, AEMPS). Long-term use can cause muscle damage, including rhabdomyolysis, as well as peripheral neuropathy and bone marrow failure (colchicine SmPC, AEMPS). Fatal and life-threatening interactions have been reported in patients who took colchicine with strong inhibitors of the enzyme CYP3A and the transporter P-glycoprotein (darunavir SmPC, European Medicines Agency, EMA).
Management
The combination is contraindicated. The Spanish summaries of product characteristics (SmPCs) of the original colchicine (1 mg and 0.5 mg tablets from one manufacturer) contraindicate colchicine during treatment with CYP3A4 or P-glycoprotein inhibitors and for 14 days afterwards (colchicine SmPCs, Spanish Agency of Medicines and Medical Devices, AEMPS). Darunavir with ritonavir or cobicistat inhibits both pathways (darunavir SmPC, European Medicines Agency, EMA). The US label of colchicine 0.5 mg for cardiovascular risk reduction lists darunavir/ritonavir among strong CYP3A4 inhibitors and also contraindicates the combination (colchicine label, US Food and Drug Administration, FDA). The darunavir documents are less strict. With either booster, they contraindicate colchicine in renal or hepatic impairment. With normal renal and hepatic function, they advise a lower colchicine dose or an interruption of colchicine treatment (darunavir SmPCs, EMA and AEMPS; darunavir FDA labels). With moderate or strong CYP3A4 inhibitors or with P-glycoprotein inhibitors, other colchicine manufacturers require a lower maximum colchicine dose and close monitoring. In renal or hepatic impairment, they advise avoiding the combination whenever possible (colchicine SmPC of another manufacturer, AEMPS). Before and during darunavir treatment, review all concomitant medicines for interactions (darunavir FDA label). At the first sign of nausea, vomiting, abdominal pain or diarrhoea, stop colchicine and refer the patient to emergency care (colchicine SmPC, AEMPS). If overdose is suspected, the patient needs an immediate medical assessment, even without symptoms, and close monitoring in hospital. There is no antidote, and haemodialysis does not remove colchicine. Within the first hour after ingestion of more than 0.1 mg/kg, consider oral activated charcoal (colchicine SmPC, AEMPS).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Colchicina Seid 0,5 mg (nº registro 78947), secciones 4.2, 4.3, 4.5 y 4.8 (2026)– AEMPS, CIMA, nº registro 78947, revisión 04/2026, secciones 4.2, 4.3, 4.5 y 4.8
- AEMPS: Ficha técnica: Colchicina Indoco 0,5 mg (nº registro 90154), secciones 4.2, 4.4 y 4.5 (2025)– AEMPS, CIMA, nº registro 90154, revisión 02/2025, secciones 4.2, 4.4 y 4.5
- FDA: Lodoco (colchicine) prescribing information (2026)– FDA, DailyMed setid ff06d68f-d65f-d097-e053-6294a90a7e5f, Agepha Pharma, revised 08/2026, sections 4 and 7 (Table 1)
- FDA: Prezista (darunavir) prescribing information (2025)– FDA, DailyMed, setid 814301f9-c990-46a5-b481-2879a521a16f, SPL 08/2025 (Revised 03/2023), sections 4 and 7 (Table 10)
- EMA: Ficha técnica: Darunavir (Prezista, EU/1/06/380), sección 4.3 (2026)– EMA SmPC vía AEMPS CIMA, nº 106380007 (EU/1/06/380), secciones 4.3 y 4.5, consultado 10/2026
- EMA: Ficha técnica: Darunavir/cobicistat (EU/1/14/967), sección 4.5 (2026)– EMA, Rezolsta 800 mg/150 mg (autorización europea por procedimiento centralizado), ficha técnica en CIMA, nº registro 114967001, consultada 10/2026, secciones 4.3 y 4.5
- AEMPS: Ficha técnica: Darunavir (Darunavir Aurovitas, nº registro 84835), sección 4.5 (2023)– AEMPS, CIMA, nº registro 84835, revisión 09/2023, secciones 4.3 y 4.5
- FDA: PREZCOBIX (darunavir and cobicistat) prescribing information (2026)– FDA, DailyMed setid 9c38fdb6-d0ba-4f16-a0e3-85d9ec334d9f (Janssen Products), revisión 02/2026 (versión 29), secciones 4, 6.2, 7.1 y 7.3
- AEMPS: Ficha técnica: Colchicina Seid 1 mg (nº registro 33720), secciones 4.3, 4.4, 4.8 y 4.9 (2026)– AEMPS, CIMA, nº registro 33720 (Colchicina Seid 1 mg comprimidos, Seid S.A., autorizado desde 1960), revisión 04/2026, secciones 4.3, 4.4, 4.5, 4.8 y 4.9